Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium-99 iPSMA - Advanced Nuclear Medicine Ingredients

Next Previous
Drug Profile

Technetium-99 iPSMA - Advanced Nuclear Medicine Ingredients

Alternative Names: 99mTc-EDDA/HYNIC-iPSMA; 99mTc-EDDA/HYNIC-Lys(Nal)-Urea-Glu; 99mTc-HYNIC-iPSMA; 99mTc-iPSMA; TLX-599-CDx

Latest Information Update: 14 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mexican National Institute of Nuclear Research
  • Developer Advanced Nuclear Medicine Ingredients; Mexican National Institute of Nuclear Research
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 14 Jun 2023 Discontinued - Phase-III for Prostate cancer (Diagnosis) in Australia (IV) (Telixpharma pipeline June 2023)
  • 04 Sep 2021 Phase-III clinical trials in Prostate cancer (Diagnosis) in Australia (IV) (Telix Pharmaceuticals pipeline, September 2021)
  • 23 Aug 2021 Telix Pharmaceuticals and Lightpoint Medical agree to explore SENSEI® and TLX599-CDx combination for detection of Prostate cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top